Weight-loss drug ecnoglutide takes aim at knee osteoarthritis pain

NCT ID NCT07734311

Not yet recruiting Symptom relief Sponsor: Hangzhou Sciwind Biosciences Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether ecnoglutide, a GLP-1 drug similar to semaglutide, can reduce knee pain and body weight in obese adults with knee osteoarthritis. Participants receive either ecnoglutide injections or a placebo for several months. The study measures changes in pain scores and weight loss percentages.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental GLP-1 drug called ecnoglutide
What this could lead to: If it works, this could offer a new treatment that eases knee pain and helps with weight loss for people with obesity-related osteoarthritis.
What could go wrong: This is an early-phase trial, so the drug may not prove effective or could cause side effects like nausea or gastrointestinal issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KNEE OSTEOARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder osteoarthritis, knee

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KNEE OSTEOARTHRITIS OBESITY

Contacts and locations

Locations

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.